Penny Stock Soars on FDA News

The company is appealing an early August FDA decision

Karee Venema

Nov 12, 2018 at 9:33 AM

PTIE

The shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) are trading up 5.6% at $1.21, after the biopharm said it is appealing the Food and Drug Administration's (FDA) decision on its pain drug, Remoxy. Back in August, the regulatory agency failed to approve Remoxy, after an advisory panel voted overwhelmingly against the treatment, citing potential abuse risks. A meeting date between the two has been set for Thursday, Jan. 31, 2019.

It's been a rough stretch for PTIE stock since that late-June FDA advisory panel ruling. Since gapping more than 71% lower on June 27, the equity has been stuck churning in penny-stock territory, with the $2.80 region -- home to its post bear-gap highs -- serving as stiff resistance.

Short sellers have been in the driver's seat throughout these technical troubles. Short interest has nearly quadrupled since mid-June. Plus, the 2.5 million PTIE shares currently sold short represents nearly 17% of the stock's available float.

Follow @Schaeffers

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.